Shigellosis is a world wide disease producing significant morbidity and in developing countries, a leading cause of diarrheal disease mortality. Pathogenesis involves invasion of colonic epithelial cells. A protein toxin is now believed to be a second improtant virulence factor. The same or very similar toxin is produced by non-invasive enteropathogenic E. coli and other organisms. The toxin molecule consists of one A chain and 5 B chains. A functional role of the B chains is to mediate toxin binding to the eukaryotic cell surface. A glycolipid has been shown to be a toxin receptor and a glycoprotein receptor with a different sugar specificity (GlcNAc3) is also involved. This proposal is designed to study basic structure-function relationships of the toxin B chain. Particular emphasis will be placed on the structrual location of the two binding domains and on their biological roles in mediating the biological activities of the toxin. Thorugh the use of the glycoprotein receptor analogue, chitotetraose, direct evidence for the two binding domains will first be documented. Since the B chains exist in multimer form in the individual monomers and/or regions of B to B interaction. A chemical cross-linker will be used to determine the inter or intra- chain location of the binding domains. By intraluminal injections of toxin with soluble receptor analogues the role of the two receptors in mediating fluid secretion in rabbits wil be analyzed. Immunization of rabbits with synthetic peptides derived from the B chain amino acid sequence will lead to antibodies that will be tested for their ability to neutralized the biological activity of toxin. Information from this study will be useful for the future design of safe and effective toxin vaccines. Finally by both specific chemical modification of the B chain and by the study of B chain mutants information on the location of amino acids involved in important B chain functions will be determined.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI020325-06
Application #
3129923
Study Section
Bacteriology and Mycology Subcommittee 1 (BM)
Project Start
1984-04-01
Project End
1990-06-30
Budget Start
1989-04-01
Budget End
1990-06-30
Support Year
6
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Tufts University
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02111
Fuchs, S; Muhldorfer, I; Donohue-Rolfe, A et al. (1999) Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens. Microb Pathog 27:13-23
Gunzer, F; Bohn, U; Fuchs, S et al. (1998) Construction and characterization of an isogenic slt-ii deletion mutant of enterohemorrhagic Escherichia coli. Infect Immun 66:2337-41
Muhldorfer, I; Hacker, J; Keusch, G T et al. (1996) Regulation of the Shiga-like toxin II operon in Escherichia coli. Infect Immun 64:495-502
Tzipori, S; Gunzer, F; Donnenberg, M S et al. (1995) The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect Immun 63:3621-7
Acheson, D W; De Breucker, S A; Jacewicz, M et al. (1995) Expression and purification of Shiga-like toxin II B subunits. Infect Immun 63:301-8
Donta, S T; Tomicic, T K; Donohue-Rolfe, A (1995) Inhibition of Shiga-like toxins by brefeldin A. J Infect Dis 171:721-4
Jacewicz, M S; Acheson, D W; Mobassaleh, M et al. (1995) Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J Clin Invest 96:1328-35
Keusch, G T; Jacewicz, M; Acheson, D W et al. (1995) Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e. Infect Immun 63:1138-41
Acheson, D W; Jacewicz, M; Kane, A V et al. (1993) One step high yield affinity purification of shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays. Microb Pathog 14:57-66
Acheson, D W (1992) Enterotoxins in acute infective diarrhoea. J Infect 24:225-45

Showing the most recent 10 out of 28 publications